Becton Dickinson & Co. closed 29.02% below its 52-week high of $251.99, which the company reached on February 3rd.

A deal for Becton Dickinson’s biosciences and diagnostic solutions unit puts Waters Corp. in a greater position to compete ...

Becton, Dickinson's divestment enhances focus, reduces leverage, funds buybacks, and unlocks value. Read more about the M&A ...

Waters said it reached a deal to buy the Biosciences & Diagnostic Solutions business of Becton Dickinson for around $17.5 ...

Any one of the majors will be thrilled to snap some of these brands because there’s very little organic growth in the ...

Life sciences firm Waters will take on $4 billion in debt, and issue 39.2% of its shares to Becton Dickinson shareholders.

Becton, Dickinson and Company is an attractive firm that just made a good deal. Click here to find out why BDX stock is a Buy ...

Lab equipment maker Waters Corp on Monday said it will buy a bioscience and diagnostics unit spun off from medtech provider ...

Heartland Advisors, an investment management company, released its “Heartland Mid Cap Value Fund” second quarter 2025 ...

Milford-based biotech company Waters Corp. will merge with Becton, Dickinson and Co.’s biosciences an diagnostic solutions ...

Becton Dickinson & Co. closed 28.21% short of its 52-week high of $251.99, which the company reached on February 3rd.